Kerry Rogers, MD

Articles

Dr. Rogers on the Safety Profile of Ianalumab/Ibrutinib in CLL

April 14th 2021

Kerry A. Rogers, MD, discusses the safety profile of the combination of ianalumab plus ibrutinib, in patients with chronic lymphocytic leukemia.

Dr. Rogers on the Next Steps With Obinutuzumab/Ibrutinib/Venetoclax in CLL

April 12th 2021

Kerry A. Rogers, MD, discusses the next steps with the triplet combination of obinutuzumab, ibrutinib, and venetoclax in chronic lymphocytic leukemia.

Dr. Rogers on Assessing MRD After Obinutuzumab/Ibrutinib/Venetoclax in CLL

January 4th 2021

Kerry Rogers, MD, discusses the minimal residual disease assessment component of a phase 2 trial evaluating obinutuzumab, ibrutinib, and venetoclax in chronic lymphocytic leukemia.

Dr. Rogers on Data for Ibrutinib in Hairy Cell Leukemia

October 25th 2019

Kerry Rogers, MD, discusses the results from an ongoing phase II trial investigating ibrutinib in patients with relapsed/refractory hairy cell leukemia. Because this represents a very rare patient population, accrual began in 2013, and these data reflect on a small portion of the 39 patients enrolled.

Dr. Rogers on Reducing Risk of Tumor Lysis Syndrome in CLL

July 26th 2018

Kerry Rogers, MD, assistant professor, Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses reducing the risk of tumor lysis syndrome during the treatment of patients with chronic lymphocytic leukemia.

Dr. Rogers on Benefits of Ibrutinib Combination in CLL

February 1st 2018

Kerry Rogers, MD, assistant professor, Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses the benefits of ibrutinib (Imbruvica) in combination with venetoclax (Venclexta) and obinutuzumab (Gazyva) for patients with chronic lymphocytic leukemia (CLL).

Dr. Rogers on Determining Patients With High-Risk CLL

January 18th 2018

Kerry Rogers, MD, assistant professor, Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses how to determine patients with high-risk chronic lymphocytic leukemia (CLL).

Dr. Rogers Discusses Obinutuzumab, Ibrutinib, and Venetoclax Combination in CLL

December 22nd 2017

Kerry Rogers, MD, assistant professor, Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses the initial results of the phase II treatment-naïve cohort in a phase Ib/II study of obinutuzumab (Gazyva), ibrutinib (Imbruvica), and venetoclax (Vencelxta) in chronic lymphocytic leukemia (CLL).

Dr. Rogers Discusses Early Intervention With Ibrutinib in CLL

December 10th 2017

Kerry Rogers, MD, Assistant Professor, Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses a phase II trial of early intervention with ibrutinib (Imbruvica) in patients with asymptomatic, high-risk chronic lymphocytic leukemia (CLL) during the 2017 ASH Annual Meeting.